Sparsentan has toxicity warning particularly related to liver toxicity, foetal toxicity and certain drug interactions - “the company will have to run a risk evaluation and mitigation strategy, or REMS, as part of the approval. It will require doctors to go through special training, and patients to be enrolled in a monitoring program, in order for the drug to be prescribed.”
DXB Media thread., page-213
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.015(3.80%) |
Mkt cap ! $228.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 41.5¢ | 39.0¢ | $1.181M | 2.922M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 260640 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 22838 | 1 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |